Biosimilar Deal Watch: Formycon/ATHOS, Fresenius/mAbxience/Ivenix, and Intas/Axantia
LexBlog IP
APRIL 8, 2022
mAbxience was founded in 2010, and has two commercialized biosimilar products (rituximab and bevacuzumab), and state of the art manufacturing facilities in Spain and Argentina.
Let's personalize your content